Multiple Myeloma: Diagnosis and Treatment
- 1 October 2005
- journal article
- review article
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 80 (10) , 1371-1382
- https://doi.org/10.4065/80.10.1371
Abstract
No abstract availableKeywords
This publication has 97 references indexed in Scilit:
- Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myelomaBlood, 2005
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- Thalidomide for Patients With Relapsed Multiple Myeloma After High-Dose Chemotherapy and Stem Cell Transplantation: Results of an Open-Label Multicenter Phase 2 Study of Efficacy, Toxicity, and Biological ActivityMayo Clinic Proceedings, 2004
- Thalidomide: Current Role in the Treatment of Non-Plasma Cell MalignanciesJournal of Clinical Oncology, 2004
- Single versus Double Autologous Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2003
- Thalidomide as initial therapy for early-stage myelomaLeukemia, 2003
- Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaBlood, 2002
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- VAD‐based regimens as primary treatment for multiple myelomaAmerican Journal of Hematology, 1990
- Long-Term Survival in Multiple MyelomaNew England Journal of Medicine, 1983